The Analgesic Effect of Remifentanil on Prevention of Withdrawal Response Associated with the Injection of Rocuronium in Children: No Evidence for a Peripheral Action
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, J. R. | - |
dc.contributor.author | Jeon, Y. | - |
dc.contributor.author | Yoo, Y. | - |
dc.contributor.author | Shin, H. J. | - |
dc.contributor.author | Ahn, J. H. | - |
dc.contributor.author | Lim, C. H. | - |
dc.date.accessioned | 2021-09-08T00:32:21Z | - |
dc.date.available | 2021-09-08T00:32:21Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2010-09 | - |
dc.identifier.issn | 0300-0605 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/115777 | - |
dc.description.abstract | Remifentanil pre-treatment has been reported to decrease the incidence of rocuronium injection-associated withdrawal movement. This study was designed to explore the site of action of remifentanil for reducing withdrawal response during rocuronium injection in children. Ninety-six paediatric patients were randomly assigned to three groups. After induction of anaesthesia with 5 mg/kg 2.5% thiopental sodium, 2 ml saline (placebo group) or 0.5 mu g/kg remifentanil (group R), was injected intravenously 1 min before 0.6 mg/kg rocuronium. In a third group (group R'), the venous retention of 0.5 mu g/kg remifentanil was maintained for 30 s followed by tourniquet release and injection of 0.6 mg/kg rocuronium. Withdrawal response was graded using a four-point scale. The incidence of withdrawal movement after rocuronium administration was 94%, 22% and 81% in the placebo, R, and R' groups, respectively. This study demonstrated that the pre-treatment effect of remifentanil for reducing rocuronium-associated withdrawal response occurs mainly through a central action. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.subject | PAIN | - |
dc.subject | PRETREATMENT | - |
dc.subject | PROPOFOL | - |
dc.subject | LIDOCAINE | - |
dc.subject | FENTANYL | - |
dc.title | The Analgesic Effect of Remifentanil on Prevention of Withdrawal Response Associated with the Injection of Rocuronium in Children: No Evidence for a Peripheral Action | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoo, Y. | - |
dc.contributor.affiliatedAuthor | Lim, C. H. | - |
dc.identifier.doi | 10.1177/147323001003800526 | - |
dc.identifier.wosid | 000285404000026 | - |
dc.identifier.bibliographicCitation | JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, v.38, no.5, pp.1795 - 1800 | - |
dc.relation.isPartOf | JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | - |
dc.citation.title | JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | - |
dc.citation.volume | 38 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1795 | - |
dc.citation.endPage | 1800 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | PAIN | - |
dc.subject.keywordPlus | PRETREATMENT | - |
dc.subject.keywordPlus | PROPOFOL | - |
dc.subject.keywordPlus | LIDOCAINE | - |
dc.subject.keywordPlus | FENTANYL | - |
dc.subject.keywordAuthor | ROCURONIUM | - |
dc.subject.keywordAuthor | REMIFENTANIL | - |
dc.subject.keywordAuthor | WITHDRAWAL RESPONSE | - |
dc.subject.keywordAuthor | CHILDREN | - |
dc.subject.keywordAuthor | PAIN | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.